

Marina B Klein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3862639/marina-b-klein-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237 papers	8,796 citations	49 h-index	86 g-index
250 ext. papers	10,263 ext. citations	5.6 avg, IF	5.5 L-index

#	Paper	IF	Citations
237	Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. <i>PLoS ONE</i> , 2013 , 8, e81355	3.7	894
236	Effect of early versus deferred antiretroviral therapy for HIV on survival. <i>New England Journal of Medicine</i> , 2009 , 360, 1815-26	59.2	852
235	Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1026-34	11.6	383
234	Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. <i>Annals of Internal Medicine</i> , 2014 , 160, 369-79	8	183
233	Late presentation for human immunodeficiency virus care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1512-20	11.6	165
232	Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 149-63	3.1	156
231	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 50-8	1.6	152
230	Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 405-13	3.1	146
229	Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007 , 36, 294-301	7.8	139
228	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. <i>Lancet, The</i> , 2018 , 392, 312-358	40	135
227	Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. <i>Sexually Transmitted Infections</i> , 2012 , 88, 558-64	2.8	126
226	Retention among North American HIV-infected persons in clinical care, 2000-2008. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 356-62	3.1	117
225	End-stage renal disease among HIV-infected adults in North America. <i>Clinical Infectious Diseases</i> , 2015 , 60, 941-9	11.6	112
224	Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 689-99	2.6	105
223	Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2012 , 7, e44611	3.7	99
222	U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. <i>Annals of Internal Medicine</i> , 2012 , 157, 325-35	8	92
221	Virologic and immunologic response to HAART, by age and regimen class. <i>Aids</i> , 2010 , 24, 2469-79	3.5	87

220	Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?. <i>Journal of the International AIDS Society</i> , 2017 , 20, 22146	5.4	85
219	The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 365-72	3.1	84
218	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1230-1238	11.6	83
217	Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. <i>BMC Infectious Diseases</i> , 2015 , 15, 274	4	82
216	Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1174-82	11.6	82
215	Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1230-8	7	80
214	Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. <i>International Journal of Epidemiology</i> , 2010 , 39, 1162-9	7.8	79
213	HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. <i>European Journal of Immunology</i> , 2010 , 40, 2493-505	6.1	78
212	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010 , 376, 340-5	4 ⁰	77
211	Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. <i>Clinical Infectious Diseases</i> , 2007 , 45, 234-40	11.6	70
210	The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. <i>Journal of Infectious Diseases</i> , 2000 , 182, 200-5	7	69
209	Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1449-58	11.6	66
208	Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand. <i>Journal of Clinical Investigation</i> , 1999 , 103, 407-12	15.9	66
207	Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). <i>Journal of the International AIDS Society</i> , 2009 , 12, 11	5.4	63
206	CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010 , 7, 45	3	63
205	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. <i>Cmaj</i> , 2018 , 190, E677-E687	3.5	62
204	Liver fibrosis progression in hepatitis C virus infection after seroconversion. <i>JAMA Internal Medicine</i> , 2015 , 175, 178-85	11.5	61
203	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. <i>Clinical Infectious Diseases</i> , 2016 , 62, 919-926	11.6	61

202	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 69, 413-21	3.1	61
201	Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1185-9	11.6	60
200	Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. <i>Aids</i> , 2010 , 24, 1857-65	3.5	60
199	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016 , 4, E605-E614	2.5	59
198	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV, the</i> , 2019 , 6, e93-e104	7.8	58
197	Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. <i>AIDS Reviews</i> , 2008 , 10, 212-23	1.5	58
196	Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfecting with HCV genotype 1 and HIV-1: a phase 3 study. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1579-87	11.6	57
195	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014 , 50, 1169-76	4.4	55
194	Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. <i>PLoS Medicine</i> , 2008 , 5, e92	11.6	54
193	Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. <i>PLoS ONE</i> , 2013 , 8, e77665	3.7	53
192	The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0141715	3.7	53
191	Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1582-90	11.6	51
190	Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 463-9	3.1	51
189	Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. <i>Clinical Infectious Diseases</i> , 2013 , 57, 663-70	11.6	49
188	Opportunistic disease and mortality in patients coinfecting with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1468-75	11.6	48
187	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 118-24	9.7	47
186	Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfecting patients following antiretroviral therapy interruption. <i>Aids</i> , 2010 , 24, 857-65	3.5	47
185	Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , 2016 , 30, 2635-2643	3.5	46

184	Association Between Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. <i>AIDS and Behavior</i> , 2017 , 21, 754-765	4.3	46
183	Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1154-1162	11.6	45
182	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. <i>Journal of Hepatology</i> , 2017 , 67, 801-808	13.4	44
181	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017 , 65, 636-643	11.6	44
180	Peering at peer review revealed high degree of chance associated with funding of grant applications. <i>Journal of Clinical Epidemiology</i> , 2006 , 59, 842-8	5.7	44
179	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1160-1167	11.6	43
178	Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). <i>Aids</i> , 2014 , 28, 1957-65	3.5	42
177	Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. <i>Aids</i> , 2011 , 25, 777-86	3.5	42
176	Pathways From HIV-Related Stigma to Antiretroviral Therapy Measures in the HIV Care Cascade for Women Living With HIV in Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 144-153	3.1	42
175	Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. <i>Clinical Infectious Diseases</i> , 2014 , 58, 719-27	11.6	41
174	Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. <i>PLoS ONE</i> , 2009 , 4, e4517	3.7	41
173	Cohort profile: the Canadian Observational Cohort collaboration. <i>International Journal of Epidemiology</i> , 2011 , 40, 25-32	7.8	40
172	Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1240-9	7	39
171	CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. <i>Gastroenterology</i> , 2011 , 140, 2064-73	13.3	39
170	Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada. <i>Women's Health Issues</i> , 2017 , 27, 721-730	2.6	37
169	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 62-72	3.1	37
168	Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. <i>Journal of the International AIDS Society</i> , 2017 , 20, e25013	5.4	37
167	A CD4+ cell count . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 451-9	3.1	37

166	Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review. <i>International Journal of Drug Policy</i> , 2018 , 57, 95-103	5.5	36
165	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 63, 821-829	11.6	35
164	Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. <i>PLoS ONE</i> , 2011 , 6, e17758	3.7	35
163	Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. <i>Aids</i> , 2009 , 23, 731-7	3.5	35
162	HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. <i>HIV Medicine</i> , 2013 , 14, 10-20	2.7	34
161	Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. <i>PLoS ONE</i> , 2013 , 8, e78548	3.7	34
160	Food insecurity and low CD4 count among HIV-infected people: a systematic review and meta-analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016 , 28, 1577-1585	2.2	33
159	Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. <i>PLoS ONE</i> , 2013 , 8, e83649	3.7	33
158	Physicians Practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014 , 28, 23-30	2.8	31
157	Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. <i>Journal of Infectious Diseases</i> , 2011 , 204, 893-901	7	31
156	Epidemiology of hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 297-302	4.2	30
155	Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. <i>BMC Infectious Diseases</i> , 2016 , 16, 590	4	29
154	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. <i>Journal of the International AIDS Society</i> , 2018 , 21 Suppl 2, e25051	5.4	27
153	Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. <i>Journal of the International AIDS Society</i> , 2014 , 17, 18944	5.4	27
152	Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. <i>Aids</i> , 2011 , 25, 967-75	3.5	26
151	Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. <i>AIDS and Behavior</i> , 2017 , 21, 792-802	4.3	25
150	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019 , 6, e240-e249	7.8	25
149	HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. <i>Vaccine</i> , 2016 , 34, 4799-806	4.1	25

148	A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. <i>BMC Infectious Diseases</i> , 2017 , 17, 140	4	24
147	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.. <i>Cmaj</i> , 2022 ,	3.5	23
146	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N12009 and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012 , 13, 23-32		21
145	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. <i>BMJ Open</i> , 2019 , 9, e024793	3	20
144	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , 2019 , 39, 2244-2260	7.9	20
143	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014 , 60, 295-300	14.5	20
142	On Bayesian estimation of marginal structural models. <i>Biometrics</i> , 2015 , 71, 279-88	1.8	20
141	Viral pathogens including human metapneumovirus are the primary cause of febrile respiratory illness in HIV-infected adults receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 201, 297-301	7	20
140	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1131-1138	11.6	20
139	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 521-526	4.2	19
138	Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , 2018 , 13, e0191985	3.7	19
137	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2234-e2242	11.6	19
136	The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019 , 68, 788-794	11.6	18
135	Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2017 , 17, 246	4	18
134	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. <i>HIV Clinical Trials</i> , 2015 , 16, 100-10		18
133	Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv015 ¹		17
132	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20024	5.4	17
131	Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfecting with HIV and hepatitis C virus. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1798-805	11.6	17

130	Are we ready for home-based, self-testing for HIV?. <i>Future HIV Therapy</i> , 2008 , 2, 515-520		17
129	Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. <i>Journal of Medical Virology</i> , 2006 , 78, 1158-63	19.7	17
128	Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2004 , 2, 521-32	5.5	17
127	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2012 , 26, 1789-94	3.5	16
126	Mycobacterium haemophilum epididymal abscess in a renal transplant patient. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 2459-60	9.7	16
125	The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. <i>Aids</i> , 2004 , 18, 1895-904	3.5	16
124	Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1507-1514	3.4	15
123	Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. <i>Antiviral Therapy</i> , 2011 , 16, 667-75	1.6	15
122	Didanosine, interferon-alfa and ribavirin. <i>Aids</i> , 2003 , 17, 1001-1008	3.5	15
121	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016 , 2016, 4385643	2.6	14
120	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. <i>American Journal of Epidemiology</i> , 2019 , 188, 2097-2109	3.8	14
119	A marginal structural model for multiple-outcome survival data: assessing the impact of injection drug use on several causes of death in the Canadian Co-infection Cohort. <i>Statistics in Medicine</i> , 2014 , 33, 1409-25	2.3	14
118	Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. <i>BMC Infectious Diseases</i> , 2010 , 10, 40	4	14
117	Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Medicine (United States)</i> , 2018 , 97, e10562	1.8	14
116	Significant differences in clinical outcomes between HIV-hepatitis C virus coinfecting individuals with and without injection drug use history. <i>Aids</i> , 2014 , 28, 121-7	3.5	13
115	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014 , 2, E318-29	2.5	13
114	Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation. <i>Biometrics</i> , 2014 , 70, 144-52	1.8	13
113	Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naïve HIV-infected patients initiating therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 38-46	3.1	13

112	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020 , 72, 431-440	13.4	13
111	Evaluating the impact of health policies: using a difference-in-differences approach. <i>International Journal of Public Health</i> , 2019 , 64, 637-642	4	13
110	HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2015 , 16, 24-31	2.7	12
109	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw050	1	12
108	Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort. <i>Drug and Alcohol Dependence</i> , 2014 , 137, 121-8	4.9	12
107	CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals. <i>PLoS ONE</i> , 2014 , 9, e101441	3.7	12
106	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfecting with HIV: a prospective cohort study. <i>CMAJ Open</i> , 2013 , 1, E106-14	2.5	12
105	Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 205-220	3.4	12
104	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020 , 34, 237-244	3.5	12
103	The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV. <i>Journal of Infectious Diseases</i> , 2017 , 216, 447-456	7	11
102	Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. <i>AIDS Research and Treatment</i> , 2015 , 2015, 923194	2.3	11
101	Noncirrhotic portal hypertension and didanosine: a re-analysis. <i>Clinical Infectious Diseases</i> , 2011 , 52, 154-161	5.6	11
100	A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008 , 19, 419-23	2.6	11
99	High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. <i>HIV Clinical Trials</i> , 2012 , 13, 23-32		11
98	Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. <i>Aids</i> , 2019 , 33, 1013-1022	3.5	11
97	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020 , 71, 363-371	11.6	11
96	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv109	1	10
95	A cloned CD15s-negative variant of HL60 cells is deficient in expression of FUT7 and does not adhere to cytokine-stimulated endothelial cells. <i>European Journal of Haematology</i> , 1999 , 63, 42-9	3.8	10

94	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 71-80	3.1	10
93	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021 , 12, 4450	17.4	10
92	Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. <i>American Journal of Epidemiology</i> , 2016 , 184, 249-58	3.8	10
91	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. <i>International Journal of Drug Policy</i> , 2019 , 65, 41-49	5.5	10
90	Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education. <i>Cannabis and Cannabinoid Research</i> , 2019 , 4, 204-213	4.6	9
89	Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz055	1	9
88	Segmented generalized mixed effect models to evaluate health outcomes. <i>International Journal of Public Health</i> , 2018 , 63, 547-551	4	9
87	Responder Interferon [Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2016 , 214, 80-6	7	9
86	Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014 , 13, 56-62	1.7	9
85	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013 , 24, 217-38	2.6	9
84	Rapid testing at labor and delivery to prevent mother-to-child HIV transmission in developing settings: issues and challenges. <i>Women's Health</i> , 2009 , 5, 55-62	3	9
83	Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. <i>American Journal of Epidemiology</i> , 2011 , 174, 727-35	3.8	9
82	Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. <i>Antiviral Therapy</i> , 2013 , 18, 717-21	1.6	9
81	CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. <i>Contemporary Clinical Trials</i> , 2008 , 29, 617-30	2.3	9
80	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25197	5.4	9
79	Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009 , 20, 51-7	2.6	8
78	Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007 , 18, 293-303	2.6	8
77	Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. <i>Hepatology</i> , 2021 , 74, 1190-1202	11.2	8

76	Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 254-62	3.1	8
75	Opioid use and risk of liver fibrosis in HIV/hepatitis C virus-coinfected patients in Canada. <i>HIV Medicine</i> , 2016 , 17, 36-45	2.7	8
74	The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. <i>CMAJ Open</i> , 2019 , 7, E674-E679	2.5	8
73	Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression. <i>Aids</i> , 2018 , 32, 1323-1332	3.5	8
72	Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. <i>Aids</i> , 2018 , 32, 751-759	3.5	7
71	Association between depressive symptoms, CD4 count and HIV viral suppression among HIV-HCV co-infected people. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018 , 30, 643-649	2.2	7
70	Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons. <i>Clinical Infectious Diseases</i> , 2016 , 62, 242-249	11.6	7
69	Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. <i>HIV Clinical Trials</i> , 2014 , 15, 161-75		7
68	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2810-2817	11.6	7
67	Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1422-1430	11.6	7
66	Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. <i>Canadian Liver Journal</i> , 2018 , 1, 231-239	0.3	7
65	A randomized pilot study assessing the acceptability of rapid point-of-care hepatitis C virus (HCV) testing among male inmates in Montreal, Canada. <i>International Journal of Drug Policy</i> , 2020 , 85, 102921	5.5	6
64	Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada. <i>Canadian Journal of Public Health</i> , 2017 , 108, e169-e175	3.2	6
63	Injection drug use, food insecurity, and HIV-HCV co-infection: a longitudinal cohort analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018 , 30, 1322-1328	2.2	6
62	A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 73, 531-539	3.1	6
61	High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. <i>Journal of Clinical Immunology</i> , 2014 , 34, 655-62	5.7	6
60	Impact of Food Insecurity on Depressive Symptoms Among HIV-HCV Co-infected People. <i>AIDS and Behavior</i> , 2017 , 21, 3464-3472	4.3	6
59	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014 , 25, 311-20	2.6	6

58	Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naïve, HIV-infected patients in Canada. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014 , 13, 153-9	1.7	6
57	Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. <i>Aids</i> , 2013 , 27, 2863-72	3.5	6
56	Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. <i>International Journal of Drug Policy</i> , 2021 , 96, 103247	5.5	6
55	Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfecting patients. <i>Aids</i> , 2016 , 30, 1403-311	3.5	6
54	Delayed linkage to HIV care among asylum seekers in Quebec, Canada. <i>BMC Public Health</i> , 2019 , 19, 16834.1	4.1	6
53	Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 6496-512	6.3	5
52	The Impact of Sparse Follow-up on Marginal Structural Models for Time-to-Event Data. <i>American Journal of Epidemiology</i> , 2015 , 182, 1047-55	3.8	5
51	Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?. <i>Clinical Infectious Diseases</i> , 2021 , 73, 468-477	11.6	5
50	Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. <i>Drug and Alcohol Dependence</i> , 2018 , 185, 374-380	4.9	5
49	Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2019 , 6,	1	5
48	Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis. <i>AIDS and Behavior</i> , 2017 , 21, 3496-3505	4.3	5
47	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study. <i>BMC Infectious Diseases</i> , 2017 , 17, 80	4	5
46	Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. <i>PLoS ONE</i> , 2015 , 10, e0129868	3.7	5
45	Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. <i>Aids</i> , 2010 , 24, 2639-44	3.5	5
44	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017 , 12, e0176282	3.7	5
43	Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging. <i>PLoS ONE</i> , 2018 , 13, e0195148	3.7	5
42	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020 , 222, 787-797	7	4
41	A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada. <i>Antiviral Therapy</i> , 2017 , 22, 325-335	1.6	4

40	Hepatitis C virus elimination: time for disruptive innovation. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25360	5.4	4
39	Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C. <i>HIV Medicine</i> , 2016 , 17, 373-9	2.7	4
38	Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?. <i>BMC Infectious Diseases</i> , 2019 , 19, 982	4	4
37	Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 729-737	5.1	4
36	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021 , 4, e2037512	10.4	4
35	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 697-704	1.9	3
34	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 266	4	3
33	Rejoinder "On Bayesian estimation of marginal structural models". <i>Biometrics</i> , 2015 , 71, 299-301	1.8	3
32	Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfected cohort. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1339-42	11.6	3
31	Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1439-1448	11.6	3
30	Evaluating Flexible Modeling of Continuous Covariates in Inverse-Weighted Estimators. <i>American Journal of Epidemiology</i> , 2019 , 188, 1181-1191	3.8	3
29	Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montréal: results from three cross-sectional studies (2005, 2009, 2018). <i>Sexually Transmitted Infections</i> , 2021 , 97, 290-296	2.8	3
28	Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. <i>Aids</i> , 2003 , 17, 1001-8	3.5	3
27	Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2020 , 150, 108-115	4	2
26	Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study. <i>AIDS Research and Treatment</i> , 2018 , 2018, 7645125	2.3	2
25	Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access. <i>Hepatology, Medicine and Policy</i> , 2017 , 2, 8		2
24	Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011 , 22, 88-96	2.6	2
23	Comparing direct acting antivirals for hepatitis C using observational data - Why and how?. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00650	3.1	2

22	Tobacco smoking and HIV-related immunologic and virologic response among individuals of the Canadian HIV Observational Cohort (CANOC). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021 , 1-10	2.2	2
21	Incomplete Modeling of the Effect of Antiretroviral Therapy on the Risk of Cardiovascular Events. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1206-7	11.6	1
20	The Mediating Role of Depressive Symptoms in the Association Between Food Insecurity and HIV Related Health Outcomes Among HIV-HCV Co-Infected People. <i>AIDS and Behavior</i> , 2020 , 24, 2188-2194	4.3	1
19	Virus subtype, ethnicity and CD4 decline in untreated HIV infection. <i>Future Virology</i> , 2014 , 9, 337-340	2.4	1
18	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 ,	2.6	1
17	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , 2021 , 224, 657-666	7	1
16	Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 230-234	3.1	1
15	Characterization of people living with HIV in a Montreal-based tertiary care center with COVID-19 during the first wave of the pandemic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021 , 1-7	2.2	1
14	Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?. <i>International Journal of Drug Policy</i> , 2021 , 96, 103343	5.5	1
13	Barriers and facilitators related to HCV treatment uptake among HIV coinfecting populations in Canada: Patients and treatment provider perceptions. <i>Canadian Liver Journal</i> ,	0.3	1
12	Tenofovir and emtricitabine resistance among antiretroviral-naïve patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019 , 24, 211-220	1.6	0
11	Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV. <i>Vaccine</i> , 2020 , 38, 3073-3078	4.1	0
10	Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. <i>HIV Therapy</i> , 2009 , 3, 189-207		0
9	Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. <i>PLoS ONE</i> , 2021 , 16, e0249836	3.7	0
8	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV.. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022 , 89, 396-404	3.1	0
7	Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.. <i>International Journal of Drug Policy</i> , 2022 , 103, 103627	5.5	0
6	Identifying risk factors for prevalent anal human papillomavirus type 16 infection in women living with HIV.. <i>PLoS ONE</i> , 2022 , 17, e0268521	3.7	0
5	Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study. <i>BMC Infectious Diseases</i> , 2015 , 15, 453	4	

4	Reply to Mandorfer et al. <i>Clinical Infectious Diseases</i> , 2013 , 56, 905-6	11.6
3	Use of Smoking Cessation Aids in a Convenience Sample of PLHIV in a Canadian Tertiary Care Clinic. <i>Open AIDS Journal</i> , 2019 , 13, 1-6	0.6
2	Clinical and demographic predictors of antiretroviral efficacy in HIV/HBV co-infected patients. <i>Jammi</i> , 2021 , 6, 137-148	1.4
1	Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV/HCV co-infected population in Canada. <i>Antiviral Therapy</i> , 2022 , 27, 135965352110676	1.6